📊 AMLX Key Takeaways
Is Amylyx Pharmaceuticals, Inc. (AMLX) a Good Investment?
Amylyx Pharmaceuticals faces severe financial distress with zero revenue, mounting operating losses of $153.3M, and negative free cash flow of $123.5M, indicating the company is burning cash at an unsustainable rate. Despite a strong cash position of $226.7M, the company's lack of commercial revenue generation combined with deteriorating fundamentals suggests existential challenges to long-term viability.
Amylyx's fundamentals are weak because revenue has fallen to zero while the company remains deeply unprofitable, with a $144.74M net loss and negative free cash flow of $123.48M. The balance sheet is still strong, supported by $226.65M of cash, minimal liabilities, and no long-term debt, but that financial cushion is being consumed by ongoing operating losses. Until the company restores a credible revenue base or materially reduces cash burn, fundamentals remain unfavorable.
Why Buy Amylyx Pharmaceuticals, Inc. Stock? AMLX Key Strengths
- Substantial cash reserves of $226.7M provides runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial risk
- Strong liquidity position with 14.27x current ratio ensures short-term solvency
- Very strong liquidity, with a 14.27x current ratio and $226.65M in cash
- Debt-free balance sheet with low total liabilities relative to equity
- Large equity base of $305.26M provides near-term financial flexibility
AMLX Stock Risks: Amylyx Pharmaceuticals, Inc. Investment Risks
- Complete revenue collapse with $0.00 in reported revenue indicates failed commercialization or major business setback
- Continuous operating losses of $153.3M with negative free cash flow of $123.5M unsustainable even with current cash reserves
- Negative ROE of -47.4% and ROA of -43.5% demonstrate value destruction and inefficient capital allocation
- High insider trading activity (22 Form 4 filings in 90 days) may signal insiders managing positions during distress
- Revenue has collapsed to $0, indicating severe commercial and growth deterioration
- Sustained operating and free cash flow losses are eroding the cash runway
- Negative ROE and ROA show the company is currently destroying shareholder capital rather than generating returns
Key Metrics to Watch
- Cash burn rate and remaining runway before capital exhaustion
- Revenue generation from approved products and clinical pipeline progress
- Operating expense reduction initiatives and path to profitability
- Quarterly operating cash burn relative to cash balance
- Evidence of revenue recovery or new product commercialization progress
Amylyx Pharmaceuticals, Inc. (AMLX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.27x current ratio provides a solid financial cushion.
AMLX Profit Margin, ROE & Profitability Analysis
AMLX vs Healthcare Sector: How Amylyx Pharmaceuticals, Inc. Compares
How Amylyx Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Amylyx Pharmaceuticals, Inc. Stock Overvalued? AMLX Valuation Analysis 2026
Based on fundamental analysis, Amylyx Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Amylyx Pharmaceuticals, Inc. Balance Sheet: AMLX Debt, Cash & Liquidity
AMLX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Amylyx Pharmaceuticals, Inc.'s revenue has grown significantly by 293% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.43 indicates the company is currently unprofitable.
AMLX Revenue Growth, EPS Growth & YoY Performance
AMLX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$34.4M | $-0.37 |
| Q2 2025 | -$1.0M | -$35.9M | $-0.46 |
| Q1 2025 | N/A | -$35.9M | $-0.42 |
| Q3 2024 | $416.0K | $1.6M | $0.30 |
| Q2 2024 | -$1.0M | $1.6M | $0.31 |
| Q1 2024 | $71.4M | $1.6M | $0.02 |
| Q3 2023 | $345.0K | $1.6M | $0.30 |
| Q2 2023 | $98.2M | $1.6M | $0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Amylyx Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
AMLX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Amylyx Pharmaceuticals, Inc. (CIK: 0001658551)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AMLX
What is the AI rating for AMLX?
Amylyx Pharmaceuticals, Inc. (AMLX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AMLX's key strengths?
Claude: Substantial cash reserves of $226.7M provides runway for operations. Minimal debt burden with 0.00x debt-to-equity ratio reduces financial risk. ChatGPT: Very strong liquidity, with a 14.27x current ratio and $226.65M in cash. Debt-free balance sheet with low total liabilities relative to equity.
What are the risks of investing in AMLX?
Claude: Complete revenue collapse with $0.00 in reported revenue indicates failed commercialization or major business setback. Continuous operating losses of $153.3M with negative free cash flow of $123.5M unsustainable even with current cash reserves. ChatGPT: Revenue has collapsed to $0, indicating severe commercial and growth deterioration. Sustained operating and free cash flow losses are eroding the cash runway.
What is AMLX's revenue and growth?
Amylyx Pharmaceuticals, Inc. reported revenue of $0.0.
Does AMLX pay dividends?
Amylyx Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find AMLX SEC filings?
Official SEC filings for Amylyx Pharmaceuticals, Inc. (CIK: 0001658551) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AMLX's EPS?
Amylyx Pharmaceuticals, Inc. has a diluted EPS of $-1.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AMLX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Amylyx Pharmaceuticals, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AMLX stock overvalued or undervalued?
Valuation metrics for AMLX: ROE of -47.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AMLX stock in 2026?
Our dual AI analysis gives Amylyx Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AMLX's free cash flow?
Amylyx Pharmaceuticals, Inc.'s operating cash flow is $-123.3M, with capital expenditures of $138.0K.
How does AMLX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -47.4% (avg: 15%), current ratio 14.27 (avg: 2).